Summary
7.54 -0.15(-1.95%)06/26/2024
Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (INO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.95 | -10.04 | -25.72 | -37.57 | 1,377.58 | 1,735.71 | 205.95 | -86.93 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.54 | |
| Open | 7.52 | |
| High | 7.66 | |
| Low | 7.36 | |
| Volume | 222,098 | |
| Change | -0.15 | |
| Change % | -1.95 | |
| Avg Volume (20 Days) | 220,614 | |
| Volume/Avg Volume (20 Days) Ratio | 1.01 | |
| 52 Week Range | 0.32 - 14.75 | |
| Price vs 52 Week High | -48.88% | |
| Price vs 52 Week Low | 2,256.28% | |
| Range | -2.90 | |
| Gap Up/Down | -0.48 | |
Fundamentals | ||
| Market Capitalization (Mln) | 199 | |
| EBIDTA | -130,659,592 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 19.25 | |
| Book Value | 5.1480 | |
| Earnings Per Share | -6.0900 | |
| EPS Estimate Current Quarter | -1.2700 | |
| EPS Estimate Next Quarter | -0.8200 | |
| EPS Estimate Current Year | -3.8500 | |
| EPS Estimate Next Year | -2.9900 | |
| Diluted EPS (TTM) | -6.0900 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -266.8629 | |
| Return on asset (TTM) | -0.3211 | |
| Return on equity (TTM) | -0.7955 | |
| Revenue TTM | 832,010 | |
| Revenue per share TTM | 0.0380 | |
| Quarterly Revenue Growth (YOY) | -0.1770 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -177,388,235 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1967 | |
| Revenue Enterprise Value | 171.5011 | |
| EBITDA Enterprise Value | -1.0943 | |
| Shares | ||
| Shares Outstanding | 25,906,600 | |
| Shares Float | 23,030,092 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 1.48 | |
| Institutions (%) | 17.82 | |
06/04 08:00 EST - prnewswire.com
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D.
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D.
05/31 16:48 EST - prnewswire.com
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa. , May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa. , May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
05/22 09:45 EST - fool.com
Better Buy: Inovio Pharmaceuticals vs. Novavax
Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.
Better Buy: Inovio Pharmaceuticals vs. Novavax
Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.
05/20 16:31 EST - seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 2nd Annual BioConnect Investor Conference Call May 20, 2024 12:30 PM ET Company Participants Jacqueline Shea - President & Chief Executive Officer Michael Sumner - Chief Medical Officer Unidentified Analyst Welcome to the H.C.
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 2nd Annual BioConnect Investor Conference Call May 20, 2024 12:30 PM ET Company Participants Jacqueline Shea - President & Chief Executive Officer Michael Sumner - Chief Medical Officer Unidentified Analyst Welcome to the H.C.
05/15 14:15 EST - seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conference Call Participants Gregory Renza - Biotechnology Equity Research Analyst, RBC Gregory Renza Let's get started and welcome back everyone to the 2024 RBC Global Health Care Conference. My name is Greg Renza, one of the Biotechnology Research Analyst here at RBC and we're pleased to be joined with Inovio Pharmaceuticals now.
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conference Call Participants Gregory Renza - Biotechnology Equity Research Analyst, RBC Gregory Renza Let's get started and welcome back everyone to the 2024 RBC Global Health Care Conference. My name is Greg Renza, one of the Biotechnology Research Analyst here at RBC and we're pleased to be joined with Inovio Pharmaceuticals now.
05/14 16:44 EST - seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Roy Buchanan Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst.
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Roy Buchanan Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst.
05/13 19:47 EST - seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Roy Buchanan - JMP Anish Nikhanj - RBC Capital Markets Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call.
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Roy Buchanan - JMP Anish Nikhanj - RBC Capital Markets Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call.
05/13 16:05 EST - prnewswire.com
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planning initiation of confirmatory trial for INO-3107 based on FDA feedback Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback Balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in April 2024 Cash runway projected into third quarter of 2025 PLYMOUTH MEETING, Pa. , May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planning initiation of confirmatory trial for INO-3107 based on FDA feedback Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback Balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in April 2024 Cash runway projected into third quarter of 2025 PLYMOUTH MEETING, Pa. , May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
05/05 08:54 EST - fool.com
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Inovio Pharmaceuticals' former two leading candidates both fell flat. The company is seeking approval for another product following positive clinical results.
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Inovio Pharmaceuticals' former two leading candidates both fell flat. The company is seeking approval for another product following positive clinical results.
04/29 08:00 EST - prnewswire.com
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024.
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024.
04/29 08:00 EST - prnewswire.com
INOVIO to Participate in Upcoming Investor Conferences in May
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences Conference Date: Tuesday, May 14, 2024 Time: 11:30 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat RBC Capital Markets 2024 Global Healthcare Conference Date: Wednesday, May 15, 2024 Time: 10:00 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat H.C.
INOVIO to Participate in Upcoming Investor Conferences in May
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences Conference Date: Tuesday, May 14, 2024 Time: 11:30 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat RBC Capital Markets 2024 Global Healthcare Conference Date: Wednesday, May 15, 2024 Time: 10:00 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat H.C.
04/15 18:39 EST - prnewswire.com
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.
03/26 18:28 EST - prnewswire.com
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
03/11 14:18 EST - schaeffersresearch.com
Call Traders Swarm Heavily Shorted Pharma Stock
Options bulls are blasting Inovio Pharmaceuticals Inc (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.
Call Traders Swarm Heavily Shorted Pharma Stock
Options bulls are blasting Inovio Pharmaceuticals Inc (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.
03/08 10:55 EST - zacks.com
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
03/06 20:25 EST - seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Company Roy Buchanan - Citizens Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call.
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Company Roy Buchanan - Citizens Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call.
03/06 16:05 EST - prnewswire.com
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) Received FDA feedback that data from completed Phase 1/2 trial can be used to submit Biological License Application (BLA) under accelerated approval program Announced plan to submit BLA to FDA under accelerated approval program in second half of 2024 Announced clinical collaboration and supply agreement with Coherus BioSciences to advance development of INO-3112 in combination with LOQTORZI™ (toripalimab-tpzi) Combination therapy to be evaluated in a planned Phase 3 trial in patients with locoregionally advanced, high-risk, HPV-16/18-positive throat cancer Clinical trial design submitted to FDA in first quarter 2024; feedback expected in second quarter Reported positive Phase 1b results for INO-4201 as a potential Ebola booster vaccine for rVSV-ZEBOV (Ervebo®) Prioritized pipeline and reduced 2023 operating expenses by 48% from 2022 Ended 2023 with $145.3 million in cash, cash equivalents, and short-term investments Projects cash runway into second quarter 2025 Management will host conference call today at 4:30 p.m. ET PLYMOUTH MEETING, Pa.
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) Received FDA feedback that data from completed Phase 1/2 trial can be used to submit Biological License Application (BLA) under accelerated approval program Announced plan to submit BLA to FDA under accelerated approval program in second half of 2024 Announced clinical collaboration and supply agreement with Coherus BioSciences to advance development of INO-3112 in combination with LOQTORZI™ (toripalimab-tpzi) Combination therapy to be evaluated in a planned Phase 3 trial in patients with locoregionally advanced, high-risk, HPV-16/18-positive throat cancer Clinical trial design submitted to FDA in first quarter 2024; feedback expected in second quarter Reported positive Phase 1b results for INO-4201 as a potential Ebola booster vaccine for rVSV-ZEBOV (Ervebo®) Prioritized pipeline and reduced 2023 operating expenses by 48% from 2022 Ended 2023 with $145.3 million in cash, cash equivalents, and short-term investments Projects cash runway into second quarter 2025 Management will host conference call today at 4:30 p.m. ET PLYMOUTH MEETING, Pa.
02/21 10:56 EST - zacks.com
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
02/21 08:00 EST - prnewswire.com
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024.
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024.